Realtime | Geld | Brief | Zeit |
---|---|---|---|
6,600 | 6,900 | 15:06 | |
6,600 | 6,900 | 15:03 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14:18 | Fortrea Holdings Non-GAAP EPS of $0.19, revenue of $710.3M | 2 | Seeking Alpha | ||
FORTREA Aktie jetzt für 0€ handeln | |||||
13:06 | Fortrea Q2 2025 slides: Revenue growth accelerates as new CEO takes helm | 2 | Investing.com | ||
12:58 | Fortrea Q2 2025: Umsatzwachstum beschleunigt sich unter neuer Führung | 1 | Investing.com Deutsch | ||
12:41 | Fortrea Holdings Inc. - 8-K, Current Report | 4 | SEC Filings | ||
12:36 | Fortrea Holdings Inc: Fortrea Reports Second Quarter 2025 Results | 14 | GlobeNewswire (Europe) | For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA... ► Artikel lesen | |
00:30 | Fortrea appoints Tracy Krumme as new head of investor relations | 1 | Investing.com | ||
00:06 | Fortrea Holdings Inc: Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations | 3 | GlobeNewswire (USA) | ||
Mo | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 61 | GlobeNewswire (Europe) | DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement... ► Artikel lesen | |
Mo | What 6 Analyst Ratings Have To Say About Fortrea Holdings | 2 | Benzinga.com | ||
07.07. | Here's Why Penn Davis McFarland Sold Fortrea Holdings (FTRE) in Q1 | 17 | Insider Monkey | ||
24.06. | Fortrea Holdings Inc: Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an | 456 | GlobeNewswire (Deutschland) | Die Zusammenarbeit ermöglicht die Prüfung von Nitrosamin-Verunreinigungen, so dass Sponsoren die akzeptable Verwendung von Rifampin in Arzneimittelwechselwirkungsstudien nachweisen könnenDurham, North... ► Artikel lesen | |
24.06. | Fortrea Enters Strategic Collaboration With Emery Pharma | 2 | RTTNews | ||
24.06. | Fortrea partners with Emery Pharma for rifampin impurity testing | 2 | Investing.com | ||
24.06. | Fortrea Holdings Inc: Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin | 350 | GlobeNewswire (Europe) | Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studiesDURHAM, N.C., June 24, 2025(Nasdaq: FTRE) (the "Company")... ► Artikel lesen | |
12.06. | Fortrea Holdings aktualisiert Anreizplan und Vorstandsmitglieder | 7 | Investing.com Deutsch | ||
12.06. | Fortrea stock rises after adopting poison pill as activists swirl | 7 | Investing.com | ||
12.06. | Fortrea Holdings Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
12.06. | Fortrea Holdings Inc: Fortrea Adopts Limited-Duration Stockholder Rights Plan | 1 | GlobeNewswire (USA) | ||
12.06. | Fortrea jumps 5% after naming Anshul Thakral as CEO | 3 | Seeking Alpha | ||
11.06. | Fortrea Appoints Anshul Thakral As CEO | 1 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BB BIOTECH | 34,300 | -1,44 % | Aktien KW 30 - Weg erst durch EU-US-Zolleinigung frei? Warten bis zum 1. August? Oder TACO? Bis dahin Einzelwerte im Fokus. News. Evotec. Almonty. Heidelberger Druck. ThyssenKrupp nucera. HELLA. Palfinger. BB Biotech. Sartorius. Berentzen. GFT. STEYR Moto | Aktien: Diese Woche Einzelwerte mit Zahlen im Fokus - Berichtssaison lässt grüssen. Puma bricht ein, Evotec nach unten durchgereicht. Aber auch das: Deutsche Bank zweistelliger Kurssprung. Und so setzte... ► Artikel lesen | |
QIAGEN | 42,920 | -0,74 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
NOVAVAX | 6,139 | +5,32 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
STRYKER | 329,90 | +0,21 % | Kurs von Stryker fällt ab (323,10 €) | Im Minus liegt gegenwärtig die Aktie von Stryker . Zuletzt zahlten Investoren für die Aktie 323,10 Euro. Für das Wertpapier von Stryker steht gegenwärtig ein Minus von 6,40 Prozent zu Buche. Das Papier... ► Artikel lesen | |
ILLUMINA | 85,06 | +0,71 % | Illumina, Inc.: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 | Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis
GAAP operating margin of 20.2% and non-GAAP operating... ► Artikel lesen | |
CRISPR THERAPEUTICS | 48,400 | +0,83 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
AAP IMPLANTATE | 1,600 | -1,23 % | aap Implantate: Vollständige Zulassung sämtlicher bislang nicht zugelassener Aktien | Bad Marienberg (www.anleihencheck.de) - Die aap Implantate AG (die "Gesellschaft") gibt bekannt, dass sämtliche bislang nicht zugelassenen Aktien der Gesellschaft (bisherige ISIN DE000A32VP65 und DE000A4096G8)... ► Artikel lesen | |
OCUGEN | 0,850 | +3,20 % | Ocugen Provides Business Update with Second Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,458 | +0,48 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 10,005 | +0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,371 | -4,13 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
EDITAS MEDICINE | 2,256 | +0,58 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
TEMPUS AI | 49,400 | -1,20 % | If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today | ||
BIOCRYST PHARMACEUTICALS | 7,316 | +1,19 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen |